Last updated: February 4, 2026
Case Overview
Teva Pharmaceuticals International GmbH filed a patent infringement lawsuit against Accord Healthcare Inc. in the United States District Court for the District of Delaware (civil docket 1:21-cv-00952). The case involves patents covering a pharmaceutical compound or formulation, with Teva asserting infringement and seeking injunctive relief, damages, and other remedies.
Key Claims and Allegations
- Teva alleges that Accord’s generic version of a branded drug infringes multiple patents held by Teva.
- The patents in dispute relate to specific formulations, methods of manufacture, or manufacturing processes.
- The complaint emphasizes patent validity, likely aiming to withstand validity challenges while asserting infringement.
- The case also raises issues related to the timely filing of a Paragraph IV certification, suggesting a paragraph IV challenge or potential carve-out provision.
Procedural Timeline
- Complaint filed: August 20, 2021.
- Answer or motions to dismiss: Filed approximately within 60 days of complaint (by October 2021).
- Patent invalidity or non-infringement defenses likely briefed within 9-12 months from filing.
- Possible settlement or trial scheduled: Estimated around late 2022 or early 2023, depending on court scheduling and case complexity.
Patent Status and Legal Context
- The patents in question likely have expiration dates beyond the proposed launch date by Accord.
- Teva’s patents include formulations or methods critical to the proprietary drug.
- The case is part of broader Hatch-Waxman litigation strategies, emphasizing patent rights protection at the biosimilar or generic entry points.
Legal Position and Strategic Implications
- Teva seeks to block Accord’s generic entry, thus maintaining market exclusivity and premium pricing.
- Accord aims to demonstrate patent invalidity or non-infringement to gain FDA approval and market entry.
- The dispute influences potential market share, pricing, and health care costs for the drug class.
Recent Developments and Industry Impact
- The case aligns with trends of aggressive patent enforcement by originators in the pharmaceutical industry.
- Similar cases have resulted in stays, settlements, or court-ordered patent invalidation.
- Industry analysts watch for indications of the court's stance on patent strength and validity challenges.
Legal and Market Outlook
- A final determination could take 1-2 years; appeals may extend litigation.
- A settlement or licensing agreement remains a possibility, especially if patent validity is contested.
- A court ruling favoring Teva preserves patent rights, whereas a ruling for Accord would facilitate generic entry.
Key Takeaways
- The case centers on patent infringement claims by Teva against Accord regarding a specific pharmaceutical formulation.
- The litigation exemplifies strategies to delay generic market entry through patent enforcement.
- Court decisions will impact both parties' market positioning and pricing strategies.
- The dispute is part of a broader pattern of patent litigation in the pharmaceutical industry.
FAQs
Q1. What is the primary patent involved in this case?
The specific patent details are confidential at this stage, but it covers a pharmaceutical formulation protected under US patent law, with a focus on certain therapeutic compounds or manufacturing methods.
Q2. What are the potential outcomes of this litigation?
Possible outcomes include a court ruling invalidating the patent, a finding of infringement, settlement agreements, or a stay pending patent validity review.
Q3. How does this case affect generic drug market entry?
If Teva prevails, it can block Accord from launching its generic version, prolonging market exclusivity. If Accord succeeds, it may enter the market sooner.
Q4. What strategic moves can Teva pursue during litigation?
Teva may seek preliminary injunctions, argument strengthening through expert testimony, or settlement negotiations to extend patent protections.
Q5. When might a final resolution occur?
Typically, cases of this nature may take 1-2 years from filing, with potential extensions for appeals.
References
- Court docket information for 1:21-cv-00952, U.S. District Court for the District of Delaware.
- Patent and litigation filings, legal databases (e.g., LexisNexis, PACER).
- Industry analysis reports on pharmaceutical patent litigation trends.
